Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response

Gastroenterology

Volumn 151, Issue 6, 2016, Pages 1131-1140.e5

  Terrault, Norah A ^a   Zeuzem, Stefan ^b   Di Bisceglie, Adrian M ^c   Lim, Joseph K ^d   Pockros, Paul J ^e   Frazier, Lynn M ^f   Kuo, Alexander ^g   Lok, Anna S ^h   Shiffman, Mitchell L ⁱ   Ben Ari, Ziv ^j   Akushevich, Lucy ^k   Vainorius, Monika ^k   Sulkowski, Mark S ^l   Fried, Michael W ^k,n   Nelson, David R ^m,n  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SCRIPPS CLINIC   (United States)

^f Liver Wellness Center   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

ⁱ Liver Institute of Virginia   (United States)

^j SHEBA MEDICAL CENTER   (Israel)

^k UNIVERSITY OF NORTH CAROLINA   (United States)

^l JOHNS HOPKINS UNIVERSITY   (United States)

^m UNIVERSITY OF FLORIDA   (United States)

ⁿ NONE

more..

Author keywords

Antiviral; DAA; NS5A Inhibitor; NS5B Inhibitor

Indexed keywords

ALBUMIN; BILIRUBIN; LACTATE DEHYDROGENASE; LEDIPASVIR PLUS SOFOSBUVIR; OMEPRAZOLE; PROTON PUMP INHIBITOR; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; SERUM ALBUMIN; URIDINE PHOSPHATE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; ATRIAL FIBRILLATION; BLACK PERSON; BRADYCARDIA; CHOLANGITIS; CHOLELITHIASIS; CHOLESTASIS; CHRONIC HEPATITIS C; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CONGESTIVE HEART FAILURE; CONVULSION; CORONARY ARTERY DISEASE; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; GENERALIZED EDEMA; GOUT; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FLUTTER; HEART INFARCTION; HEART PALPITATION; HEPATIC ENCEPHALOPATHY; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERGLYCEMIA; INFECTION; INFESTATION; INSOMNIA; JAUNDICE; KIDNEY GRAFT REJECTION; LACTIC ACIDOSIS; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; OBSERVATIONAL STUDY; PANCYTOPENIA; PREDICTIVE VALUE; PRIORITY JOURNAL; PRURITUS; RASH; RELAPSE; SICK SINUS SYNDROME; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; SUSTAINED VIROLOGIC RESPONSE; TACHYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TREATMENT FAILURE; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BENZIMIDAZOLES; BILIRUBIN; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RIBAVIRIN; RISK FACTORS; SERUM ALBUMIN; SUSTAINED VIROLOGIC RESPONSE; TIME FACTORS; TREATMENT FAILURE; URIDINE MONOPHOSPHATE; YOUNG ADULT;

EID: 84997234851     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.08.004     Document Type: Article

References (12)

1. 1 Kowdley, K.V., Gordon, S.C., Reddy, K.R., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370 (2014), 1879–1888.
2. 2 American Association for the Study of Liver Disease/Infectious Disease Society of America. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed October 11, 2016.
3. 3 Gordon, S.C., Muir, A.J., Lim, J.K., et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J Hepatol 62 (2015), 286–293.
4. 4 Sulkowski, M.S., Vargas, H.E., Di Bisceglie, A.M., et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology 150 (2016), 419–429.
5. 5 Harris, P., Taylor, R., Thielke, R., et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42 (2009), 377–381.
6. 6 Firth, D., Bias reduction of maximum likelihood estimates. Biometrika 80 (1993), 27–38.
7. 7 Afdhal, N., Reddy, K.R., Nelson, D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370 (2014), 1483–1493.
8. 8 Lawitz, E., Poordad, F.F., Pang, P.S., et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 383 (2014), 515–523.
9. 9 O'Brien, T., Feld, J., Kottilil, S., et al. No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL. Hepatology 63 (2016), 28–30.
10. 10 Harvoni package insert. http://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf. Accessed July 12, 2016.
11. 11 Reddy, K.R., Bourliere, M., Sulkowski, M., et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 62 (2015), 79–86.
12. 12 Bourliere, M., Bronowicki, J.P., de Ledinghen, V., et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 15 (2015), 397–404.